19th Ave New York, NY 95822, USA

ABOUT US

Kermode is an American privately-held, biotechnology company focused on solving the challenges of animal health. Our immediate focus is on livestock viruses such as African Swine Fever Virus (ASFV) and Swine Flu (SIV or S-OIV). Our current pipeline includes 2 products and is focused on both therapeutic antibodies and immune-stimulating vaccine proteins against ASFV:

KT100
ASFV vaccine

KT101
therapeutic antibody

ABOUT AFRICAN SWINE FEVER VIRUS

The spread ASFV has devastated the commercial swine industries in Europe, Russia, and most recently China, resulting in billions of lost dollars and the loss of a major nutritional staple. It is a matter of time before ASFV infiltrates North American livestock.

ASFV is a highly contagious viral pathogen that swiftly infects swine livestock.

Once the swine are infected, the virus will kill the animal within 24 to 48 hours.

The mortality rate for ASFV-infected animals is 100%.

OUR APPROACH

We are utilizing computational approaches to define vulnerable targets in viral structure, genetic composition and replication cycles. Once these targets are defined, we deploy state-of-the-art antibody discovery platforms to isolate therapeutic candidates with the highest potential to protect livestock against viral infections. This approach will allow Kermode to identify strong antibody therapeutics and construct vaccine candidates with long-lasting in vivo responses.

ASFV THERAPEUTIC DEVELOPMENT PIPELINE

ANTIBODY AND VIRAL PROTEIN DEVELOPMENT FOR THERAPEUTIC / VACCINE APPLICATIONS

Antibody & Protein Discovery

B/CHO
Hybrid

Ab
Amplify

Protein
Synthesis

Swine Animal Studies and Regulatory (Foreign)

Market
Approval

For therapeutic antibody vaccine and protein vaccine

ASFV THERAPEUTIC DEVELOPMENT PIPELINE

ANTIBODY AND VIRAL PROTEIN DEVELOPMENT FOR THERAPEUTIC / VACCINE APPLICATIONS

  • Antibody & Protein Discovery
  • B/CHO Hybrid
  • Ab Amplify
  • Protein Synthesis
  • Swine Animal Studies and Regulatory (Foreign)
  • Market Approval
  • For therapeutic antibody vaccine and protein vaccine

BOARD OF DIRECTORS

Kermode’s corporate governance is monitored through experienced biotechnology professionals with deep experience in the field.

Dan Chen, MBA

Tom Malcolm, PhD

Safia Rizvi, PhD

Heng Xie, PhD

OUR TEAM

Our goal is to provide an exceptional level of research, and we aim for lasting partnerships with our partners and our global communities.

Dan Chen, MBA

Founder & CEO

Tom Malcolm, PhD

Founder & COO

Ed Robb, DVM, MS, DACVN

Chief of Regulatory and Veterinarian Affairs

Jeff Chen, MBA

Business Operations, China

Tony Chen, PhD

CSO

Ken Kohn, PhD

EVP of Licensing Operations

PARTNERS

INVESTORS & PARTNERS

Access our technical approaches and detailed pipeline information